An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals
Saudi Pharmaceutical Journal · 2023-02 · 31 (2) · 295-311
DOI: 10.1016/j.jsps.2022.12.010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Saudi Pharmaceutical Journal, 2023-02. Verfasst von Wisut Wichitnithad und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Analytical Development, Pharma Nueva Co., Ltd, Bangkok 10900, Thailand. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Over the last two years, global regulatory authorities have raised safety concerns on nitrosamine contamination in several drug classes, including angiotensin II receptor antagonists, histamine-2 receptor antagonists, antimicrobial agents, and antidiabetic drugs. To avoid carcinogenic and mutagenic effects in patients relying on these medications, authorities have established specific guidelines in risk assessment scenarios and proposed control limits for nitrosamine impurities in pharmaceuticals. In this review, nitrosation pathways and possible root causes of nitrosamine formation in pharmaceuticals are discussed. The control limits of nitrosamine impurities in pharmaceuticals proposed by national regulatory authorities are presented. Additionally, a practical and science-based strategy for implementing the well-established control limits is notably reviewed in terms of an alternative approach for drug product N-nitrosamines without published AI information from animal carcinogenicity testing. Finally, a novel risk evaluation strategy for predicting and investigating the possible nitrosation of amine precursors and amine pharmaceuticals as powerful prevention of nitrosamine contamination is addressed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Analytical Development, Pharma Nueva Co., Ltd, Bangkok 10900, Thailand.
- Department of Clinical Development, Pharma Nueva Co., Ltd, Bangkok 10900, Thailand.
- Department of Ethical Business Development, Siam Pharmaceutical Co., Ltd, Bangkok 10900, Thailand.
- Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
- Center of Excellence in Natural Products for Ageing and Chronic Diseases, Chulalongkorn University, Bangkok 10330, Thailand.
Zitieren
APA
Wichitnithad, W., Nantaphol, S., Noppakhunsomboon, K., & Rojsitthisak, P. (2023). An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals. Saudi Pharmaceutical Journal, 31(2), 295-311. https://doi.org/10.1016/j.jsps.2022.12.010
Vancouver
Wichitnithad W, Nantaphol S, Noppakhunsomboon K, Rojsitthisak P. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals. Saudi Pharmaceutical Journal. 2023;31(2):295-311. doi:10.1016/j.jsps.2022.12.010
BibTeX
@article{Wichitnithad2023,
author = {Wichitnithad, Wisut and Nantaphol, Siriwan and Noppakhunsomboon, Kachathong and Rojsitthisak, Pornchai},
title = {An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals},
journal = {Saudi Pharmaceutical Journal},
year = {2023},
volume = {31},
number = {2},
pages = {295--311},
doi = {10.1016/j.jsps.2022.12.010}
}
EUVIMED